Globus Medical Inc banner

Globus Medical Inc
NYSE:GMED

Watchlist Manager
Globus Medical Inc Logo
Globus Medical Inc
NYSE:GMED
Watchlist
Price: 91.34 USD 1.29% Market Closed
Market Cap: $12.4B

P/E

22.9
Current
44%
Cheaper
vs 3-y average of 41

Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.

P/E
22.9
=
Market Cap
$12B
/
Net Income
$537.9m

Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.

P/E
22.9
=
Market Cap
$12B
/
Net Income
$537.9m

Valuation Scenarios

Globus Medical Inc is trading below its 3-year average

If P/E returns to its 3-Year Average (41), the stock would be worth $163.16 (79% upside from current price).

Statistics
Positive Scenarios
3/4
Maximum Downside
0%
Maximum Upside
+88%
Average Upside
47%
Scenario P/E Value Implied Price Upside/Downside
Current Multiple 22.9 $91.34
0%
3-Year Average 41 $163.16
+79%
5-Year Average 43.2 $171.92
+88%
Industry Average 27.6 $109.88
+20%
Country Average 22.9 $91.07
0%

Forward P/E
Today’s price vs future net income

Today's Market Cap Net Income Forward P/E
$12B
/
Jan 2026
$537.9m
=
22.9
Current
$12B
/
Dec 2026
$616.7m
=
19.4
Forward
$12B
/
Dec 2027
$683.7m
=
17.5
Forward
$12B
/
Dec 2028
$758m
=
15.8
Forward
$12B
/
Dec 2029
$859.5m
=
13.9
Forward
$12B
/
Dec 2030
$935.3m
=
12.8
Forward

Forward P/E shows whether today’s P/E still looks high or low once future net income are taken into account.

Market Distribution

In line with most companies in the United States of America
Percentile
50th
Based on 8 489 companies
50th percentile
22.9
Low
0 — 15.3
Typical Range
15.3 — 33.2
High
33.2 —
Distribution Statistics
the United States of America
Min 0
30th Percentile 15.3
Median 22.9
70th Percentile 33.2
Max 1 826 183.3

Globus Medical Inc
Glance View

Globus Medical Inc., founded in 2003, has crafted a distinctive narrative in the landscape of medical technology, rooted in innovation and practicality. Emerging from a profound understanding of spinal pathologies, the company has steadily risen to become a pivotal player in the musculoskeletal sector. Its journey is steered by a commitment to addressing complex spine disorders through the development of cutting-edge products that are not only innovative but also substantially user-friendly for both surgeons and patients. This fusion of technology and practicality is what sets Globus Medical apart. The company relentlessly focuses on expanding its product offerings through significant investments in research and development, continuously pushing the envelope in areas such as minimally invasive surgery, advanced surgical approaches, and imaging, which form the core of its business operations. The heart of Globus Medical's revenue model lies in its expansive product portfolio that serves surgeons and healthcare institutions globally. Their financial engine is powered by the sales of implants and related surgical instruments, meticulously designed to improve surgical outcomes. These products span a wide array of offerings including but not limited to advanced minimally invasive techniques and sophisticated trauma solutions. Beyond the traditional revenue streams, Globus Medical has ventured into promising areas like robotic surgery, thereby augmenting its revenue sources while accessing the benefits of technological advancements. This strategic direction not only strengthens its market position but also ensures it stays at the forefront of providing value-based solutions in the ever-evolving healthcare landscape. By integrating its technological prowess with a deep understanding of clinical needs, Globus Medical continues to carve a robust path for sustainable growth and leadership in the medtech sector.

GMED Intrinsic Value
80.52 USD
Overvaluation 12%
Intrinsic Value
Price $91.34
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett